Your browser doesn't support javascript.
loading
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology.
Zhang, Xuchao; Liang, Zhiyong; Wang, Shengyue; Lu, Shun; Song, Yong; Cheng, Ying; Ying, Jianming; Liu, Weiping; Hou, Yingyong; Li, Yangqiu; Liu, Yi; Hou, Jun; Liu, Xiufeng; Shao, Jianyong; Tai, Yanhong; Wang, Zheng; Fu, Li; Li, Hui; Zhou, Xiaojun; Bai, Hua; Wang, Mengzhao; Lu, You; Yang, Jinji; Zhong, Wenzhao; Zhou, Qing; Yang, Xuening; Wang, Jie; Huang, Cheng; Liu, Xiaoqing; Zhou, Xiaoyan; Zhang, Shirong; Tian, Hongxia; Chen, Yu; Ren, Ruibao; Liao, Ning; Wu, Chunyan; Zhu, Zhongzheng; Pan, Hongming; Gu, Yanhong; Wang, Liwei; Liu, Yunpeng; Zhang, Suzhan; Liu, Tianshu; Chen, Gong; Shao, Zhimin; Xu, Binghe; Zhang, Qingyuan; Xu, Ruihua; Shen, Lin; Wu, Yilong.
Afiliação
  • Zhang X; Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Liang Z; Affiliated Guangdong Provincial People's Hospital, South China University of Technology, Guangzhou 510630, China.
  • Wang S; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100006, China.
  • Lu S; National Research Center for Translational Medicine, Shanghai, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China.
  • Song Y; Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Cheng Y; Division of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210029, China.
  • Ying J; Department of Oncology, Jilin Cancer Hospital, Changchun 132002, China.
  • Liu W; Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, China.
  • Hou Y; Department of Pathology, West China Hospital, Sichuan University, Chengdu 610065, China.
  • Li Y; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200433, China.
  • Liu Y; Department of Hematology, First Affiliated Hospital, Institute of Hematology, School of Medicine, Jinan University, Guangzhou 519000, China.
  • Hou J; Laboratory of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
  • Liu X; Department of Oncology, First Clinical College of South China University of Technology/Guangdong Lung Cancer Institute, Guangzhou 510060, China.
  • Shao J; People's Liberation Army Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing 210046, China.
  • Tai Y; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 519000, China.
  • Wang Z; Department of Pathology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
  • Fu L; Department of Pathology, Beijing Hospital, Beijing 100071, China.
  • Li H; Department of Breast Cancer Pathology and Research Laboratory of Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, Ch
  • Zhou X; Department of Oncology, Jilin Cancer Hospital, Changchun 132002, China.
  • Bai H; Department of Pathology, Jinling Hospital Nanjing University School of Medicine, Nanjing 210029, China.
  • Wang M; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, China.
  • Lu Y; Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100006, China.
  • Yang J; Department of Oncology, West China Hospital, Sichuan University, Chengdu 610065, China.
  • Zhong W; Guangdong Lung Cancer Institute, Guangdong Provincical Prople's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincical Prople's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Yang X; Guangdong Lung Cancer Institute, Guangdong Provincical Prople's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Wang J; Guangdong Lung Cancer Institute, Guangdong Provincical Prople's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Huang C; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, China.
  • Liu X; Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350001, China.
  • Zhou X; Department of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, China.
  • Zhang S; Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai 200433, China.
  • Tian H; Center for Translational Medicine, Hangzhou First People's Hospital, Nanjing Medical University, Nanjing 210029, China.
  • Chen Y; Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Ren R; Affiliated Guangdong Provincial People's Hospital, South China University of Technology, Guangzhou 510630, China.
  • Liao N; Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Wu C; Affiliated Guangdong Provincial People's Hospital, South China University of Technology, Guangzhou 510630, China.
  • Zhu Z; State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China.
  • Pan H; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
  • Gu Y; Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200240, China.
  • Wang L; Department of Oncology, No. 113 Hospital of People's Liberation Army, Ningbo 315040, China.
  • Liu Y; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310020, China.
  • Zhang S; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
  • Liu T; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China.
  • Chen G; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110016, China.
  • Shao Z; Department of Oncology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310020, China.
  • Xu B; Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200433, China.
  • Zhang Q; Department of Colorectal, Sun Yat-sen University Cancer Center, Guangzhou 519000, China.
  • Xu R; Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200433, China.
  • Shen L; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006, China.
  • Wu Y; Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin 150030, China.
Cancer Biol Med ; 16(1): 189-204, 2019 Feb.
Article em En | MEDLINE | ID: mdl-31119060
ABSTRACT
Next-generation sequencing (NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously. Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology (CSCO) and the China Actionable Genome Consortium (CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians, pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure (SOP), data analysis, report, and NGS platform certification and validation.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Cancer Biol Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Cancer Biol Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China